Individualizing quality-of-life outcomes reporting: How localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function

Journal of Clinical Oncology

Volumn 27, Issue 24, 2009, Pages 3916-3922

  Chen, Ronald C ^a   Clark, Jack A ^a   Talcott, James A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRACHYTHERAPY; DISTRESS SYNDROME; EXTERNAL BEAM RADIOTHERAPY; FUNCTIONAL ASSESSMENT; HUMAN; INTESTINE FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER SYMPTOM INDICES; PROSTATECTOMY; QUALITY OF LIFE; SCORING SYSTEM; SELF REPORT; SEXUAL FUNCTION; URINARY TRACT OBSTRUCTION; DEFECATION; MICTURITION; MIDDLE AGED; PATHOPHYSIOLOGY; PROSTATE TUMOR; PSYCHOLOGICAL ASPECT; SEXUAL BEHAVIOR;

AGED; AGED, 80 AND OVER; DEFECATION; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SEXUAL BEHAVIOR; URINATION;

EID: 69849095945     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.6486     Document Type: Article

References (33)

1. Epstein RM, Street RL Jr: Patient-Centered Communication in Cancer Care: Promoting Healing and Reducing Suffering. Bethesda, MD, National Cancer Institute, NIH Publication 07-6225, 2007
2. Institute of Medicine: From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC, National Academy Press, 2005
3. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
4. D'Amico AV, Whittington R, Kaplan I, et al: Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. Int J Radiat Oncol Biol Phys 37:1053-1058, 1997
5. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
6. Soloway M, Roach M 3rd: Prostate cancer progression after therapy of primary curative intent: A review of data from prostate-specific antigen era. Cancer 104:2310-2322, 2005
7. Potosky AL, Davis WW, Hoffman RM, et al: Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The prostate cancer outcomes study. J Natl Cancer Inst 96:1358-1367, 2004
8. Potosky AL, Legler J, Albertsen PC, et al: Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 92: 1582-1592, 2000
9. Litwin MS, Flanders SC, Pasta DJ, et al: Sexual function and bother after radical prostatectomy or radiation for prostate cancer: Multivariate quality-of-life analysis from CaPSURE-Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 54:503-508, 1999
10. Litwin MS, Pasta DJ, Yu J, et al: Urinary function and bother after radical prostatectomy or radiation for prostate cancer: A longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 164:1973-1977, 2000
11. Litwin MS, Sadetsky N, Pasta DJ, et al: Bowel function and bother after treatment for early stage prostate cancer: A longitudinal quality of life analysis from CaPSURE. J Urol 172:515-519, 2004
12. Penson DF, Feng Z, Kuniyuki A, et al: General quality of life 2 years following treatment for prostate cancer: What influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol 21:1147-1154, 2003
13. Stanford JL, Feng Z, Hamilton AS, et al: Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA 283:354-360, 2000
14. Talcott JA, Manola J, Clark JA, et al: Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 21:3979-3986, 2003
15. Wei JT, Dunn RL, Sandler HM, et al: Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20:557-566, 2002
16. Talcott JA, Rieker P, Clark JA, et al: Patientreported symptoms after primary therapy for early prostate cancer: Results of a prospective cohort study. J Clin Oncol 16:275-283, 1998
17. Litwin MS, Gore JL, Kwan L, et al: Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 109:2239-2247, 2007
18. Sanda MG, Dunn RL, Michalski J, et al: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250-1261, 2008
19. Burnett AL: Erectile dysfunction following radical prostatectomy. JAMA 293:2648-2653, 2005
20. Schover LR, Fouladi RT, Warneke CL, et al: Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer 95:1773-1785, 2002
21. Frank SJ, Pisters LL, Davis J, et al: An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 177:2151-2156, discussion 2156, 2007
22. Krupski TL, Saigal CS, Litwin MS: Variation in continence and potency by definition. J Urol 170: 1291-1294, 2003
23. Talcott JA, Clark JA, Manola J, et al: Bringing prostate cancer quality of life research back to the bedside: Translating numbers into a format that patients can understand. J Urol 176:1558-1563, discussion 1563-1564, 2006
24. Bruner DW, Bryan CJ, Aaronson N, et al: Issues and challenges with integrating patientreported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol 25:5051-5057, 2007
25. Greenfield S, Aronow HU, Elashoff RM, et al: Flaws in mortality data: The hazards of ignoring comorbid disease. JAMA 260:2253-2255, 1988
26. Clark JA, Talcott JA: Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care 39:1118-1130, 2001
27. Cohen J: A power primer. Psychol Bull 112: 155-159, 1992
28. Khanna D, Furst DE, Wong WK, et al: Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Qual Life Res 16:1083-1092, 2007
29. Dandapani SV, Sanda MG: Measuring healthrelated quality of life consequences from primary treatment for early-stage prostate cancer. Semin Radiat Oncol 18:67-72, 2008
30. Downs TM, Sadetsky N, Pasta DJ, et al: Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer-data from CaPSURE. J Urol 170:1822-1827, 2003
31. Speight JL, Elkin EP, Pasta DJ, et al: Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: Data from CaPSURE. Int J Radiat Oncol Biol Phys 60:1066-1075, 2004
32. Cooperberg MR, Lubeck DP, Penson DF, et al: Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: Data from CaPSURE. J Urol 170:905-908, 2003
33. Litwin MS, McGuigan KA: Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. J Clin Oncol 17: 2882-2888, 1999